All of our BARD1 mutation carriers developed high-grade breast cancer, while only 44.7% of BRCA2 mutation carriers (p-value = 0.004) and 39.7% of mutation-negative patients (p-value < 0.001) developed high-grade breast cancer. Here, BARD1 is linked to breast carcinoma.